Adalimumab (Humira), of Abbvie, is the biosimilar medicine that provides the most savings to the National system of health. According to the latest report from the Spanish Association of Biosimilars (Biosim) "Analysis of the budgetary impact of biosimilar medicines in the Spanish National Health System (2009-2022)", this drug could generate savings this year of approximately 270 millones de euros.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
1 comment
Pingback: Biosimilars: the fast way to universalize the most cutting-edge treatments | West Observer